非配制聚多卡醇1%泡沫与热消融治疗慢性静脉功能不全的活体网络Meta分析更新
该活体网络Meta分析定期更新,比较非配制聚多卡醇1%泡沫与热消融治疗下肢躯干静脉功能不全的疗效与安全性。共纳入24项研究、235,413例患者,结果显示两者在静脉闭合、深静脉血栓、生活质量/症状改善及溃疡愈合方面均无统计学显著差异。
要点
- 聚多卡醇1%泡沫与热消融的静脉闭合无统计学差异(OR 0.71,95%CI 0.42–1.21)。
- 深静脉血栓风险无证据增加(OR 0.83,95%CI 0.29–2.43)。
- 生活质量/症状改善复合终点无统计学差异(Hedges' g 0.04,95%CI -0.16–0.25)。
核心结论
- 更新结果强化原结论:聚多卡醇1%泡沫与热消融在静脉闭合或深静脉血栓方面无统计学差异。
- 生活质量/症状改善复合终点及溃疡愈合也无证据显示统计学显著差异。
研究设计与样本
- 活体网络Meta分析,按预设方案每季度检索至2026年3月。
- 共纳入24项研究,235,413例患者。
主要发现
- 静脉闭合:OR 0.71(95%CI 0.42–1.21),无统计学差异。
- 最长随访敏感性分析(平均28个月,范围12–72个月):OR 0.71(95%CI 0.45–1.11)。
- 深静脉血栓:OR 0.83(95%CI 0.29–2.43),无证据显示风险增加。
- 生活质量/症状改善:Hedges' g 0.04(95%CI -0.16–0.25),无统计学差异,但网络未完全连接。
- 溃疡愈合数据有限,探索性分析未发现统计学显著差异。
临床怎么用
- 对于下肢躯干静脉功能不全的成人患者,聚多卡醇1%泡沫可作为热消融的替代选择之一。
- 决策时需考虑生活质量/症状改善证据网络未完全连接的局限性。
局限性
- 生活质量/症状改善的网络未完全连接。
- 溃疡愈合数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We previously published a network meta-analysis showing no statistically significant difference between commercially manufactured polidocanol 1% endovenous microfoam and endovenous thermal ablation for vein closure or deep vein thrombosis, when polidocanol endovenous microfoam was distinguished from physician-compounded foam. This living network meta-analysis updates the previous analysis comparing the effectiveness and safety of polidocanol endovenous microfoam ablation versus endovenous thermal ablation for the primary treatment of adult patients with venous insufficiency caused by lower-extremity truncal vein incompetence. METHODS: Systematic review searches following the prespecified protocol were conducted quarterly through March 2026. No changes were made to selection criteria. Vein closure, deep venous thrombosis, and ulcer healing were summarized as odds ratios with 95% confidence intervals. A composite outcome of disease-specific quality of life or symptom improvement scales was summarized with Hedges' g standardized mean difference. RESULTS: The updated search yielded 507 new citations and 11 new eligible studies, for a total of 24 studies (235,413 patients). Polidocanol endovenous microfoam was not statistically different from endovenous thermal ablation for vein closure (odds ratio 0.71, 95% confidence interval 0.42 to 1.21). A sensitivity analysis at longest follow-up (mean 28 months, range 12-72 months) showed similar results (odds ratio 0.71, 95% confidence interval 0.45 to 1.11). There was no evidence of increased deep venous thrombosis risk with polidocanol endovenous microfoam versus endovenous thermal ablation (odds ratio 0.83, 95% confidence interval 0.29 to 2.43). Post-treatment improvement in disease-specific quality of life or venous insufficiency symptoms showed no statistically significant difference between polidocanol endovenous microfoam and endovenous thermal ablation (standardized mean difference [Hedges' g] 0.04, 95% confidence interval -0.16 to 0.25), though the network was not fully connected. Finally, ulcer healing data was limited, but an exploratory analysis found no evidence of a statistically significant difference. CONCLUSIONS: This living network meta-analysis update reinforced the original findings that polidocanol 1% endovenous microfoam is not statistically different from endovenous thermal ablation for venous closure or deep venous thrombosis in the treatment of chronic venous insufficiency, and adds new preliminary information on outcomes relevant to the patient experience. There was no evidence of a statistically significant difference between polidocanol endovenous microfoam ablation and endovenous thermal ablation for a composite of disease-specific quality of life and symptom improvement, or for ulcer healing. The living approach maintains rigor and efficiently keeps evidence current as new studies emerge.
引用
- Kabnick LS, Esponda OL, Jimenez JC, et al. Update of a Living Network Meta-Analysis Comparing Non-compounded Polidocanol 1% Endovenous Microfoam (Varithena) Ablation versus Endovenous Thermal Ablation in Chronic Venous Insufficiency. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42933600. doi:10.1016/j.jvsv.2026.102648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。